Working… Menu

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04597541
Recruitment Status : Not yet recruiting
First Posted : October 22, 2020
Last Update Posted : October 22, 2020
Information provided by (Responsible Party):

Tracking Information
First Submitted Date  ICMJE October 16, 2020
First Posted Date  ICMJE October 22, 2020
Last Update Posted Date October 22, 2020
Estimated Study Start Date  ICMJE October 2020
Estimated Primary Completion Date May 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 16, 2020)
  • Number of participants with adverse events (AEs) [ Time Frame: From time ICF is signed until 90 days after last dose of AK112 ]
    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. temporally associated with the use of study treatment, whether or not considered related to the study treatment
  • Number of participants with DLTs [ Time Frame: During the first four weeks of treatment ]
    DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: October 16, 2020)
  • Objective response rate (ORR) [ Time Frame: Up to 2 years ]
    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1
  • Disease control rate (DCR) [ Time Frame: Up to 2 years ]
    The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD at 16 and 24 weeks respectively) based on RECIST Version 1.1.
  • Progression-free survival (PFS) [ Time Frame: Up to 2 years ]
    Progression-free survival is defined as the time from the start of treatment with AK112 until the first documentation of disease progression or death due to any cause, whichever occurs first.
  • Overall survival (OS) [ Time Frame: Up to 2 years ]
    Overall survival is defined as the time from the start of treatment with AK112 until death due to any cause.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Official Title  ICMJE A Phase I/II Trial of AK112 in Advanced Solid Tumor
Brief Summary This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary end points are objective response rate,progression-free survival and overall survival per RECIST1.1.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Solid Tumor, Adult
Intervention  ICMJE Drug: AK112
AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
Study Arms  ICMJE Experimental: 1
Intervention: Drug: AK112
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: October 16, 2020)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 2023
Estimated Primary Completion Date May 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Aged 18 to 75 years old (at the time consent is obtained);
  • Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures);
  • Have histologically- or cytologically-confirmed diagnosis of advanced solid tumor;
  • Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy;
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
  • Subject must have at least one measurable lesion according to RECIST Version1.1;
  • Adequate organ function;
  • Females of childbearing potential and non-sterilized males who are sexually active must use an effective method;
  • Adequate life expectancy.

Exclusion Criteria:

  • History of severe hypersensitivity reactions to other mAbs;
  • Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria;
  • Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery;
  • Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK112 except for treatment with small-molecule tyrosine kinase-targeted agents within 2 weeks prior to the first dose of AK112;
  • History of primary immunodeficiency;
  • Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis);
  • History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives;
  • Known allergy or reaction to any component of the AK112 formulation;
  • History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies;
  • Known history of tuberculosis;
  • Known history of HIV;
  • Receipt of live attenuated vaccination within 30 days prior to the first dose of AK112;
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE China
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04597541
Other Study ID Numbers  ICMJE AK112-102
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Akeso
Study Sponsor  ICMJE Akeso
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Akeso
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP